By Lynda Williams, medwireNews Reporter
medwireNews: Low-dose olanzapine significantly protects against nausea and vomiting compared with placebo for women with breast cancer receiving anthracycline plus cyclophosphamide chemotherapy, show phase 3 trial findings published in The Lancet Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © KatarzynaBialasiewicz / Getty Images / iStock
